Welcome to our dedicated page for CVRx SEC filings (Ticker: CVRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVRx, Inc. filings document a Nasdaq-listed medical device company commercializing Barostim neuromodulation therapy for cardiovascular disease. Its Form 8-K reports record financial results releases, preliminary operating updates, material agreements, equity offering arrangements, amendments to its loan and security agreement, and executive compensation actions tied to performance stock units.
Proxy filings describe annual meeting matters, director elections, auditor ratification, board structure and stockholder voting procedures. The company’s SEC record also identifies its common stock, emerging growth company status, governance disclosures and capital-structure matters associated with debt and at-the-market equity financing.
CVRx director-associated entity reports open-market share purchase. Treo Ventures I, L.P., an entity for which director Mudit K. Jain is the general partner, bought 46,800 shares of CVRx common stock on February 20, 2026 at a weighted average price of $6.3588 per share, with individual prices ranging from $5.8500 to $6.3868. Jain also directly holds 5,650 common shares after these transactions.
CVRx, Inc. director Mudit K. Jain reported an open-market purchase of 600 shares of common stock at a weighted average price of $4.6417 per share on February 18, 2026. Following this transaction, he directly holds 5,650 common shares.
In addition, 933,383 common shares are held indirectly through Treo Ventures I, L.P., where Jain is the general partner and shares voting and dispositive power. He disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.
CVRx, Inc. is a commercial-stage medical device company focused on Barostim, a minimally invasive neuromodulation implant for patients with heart failure with reduced ejection fraction (HFrEF). Barostim is FDA-approved, has expanded labeling, and is reimbursed by Medicare in U.S. inpatient and outpatient settings.
For the year ended December 31, 2025, CVRx generated $56.7 million in revenue with an 85% gross margin, compared to $51.3 million and 84% in 2024. Net loss was $53.3 million versus $60.0 million, and the accumulated deficit reached $590.7 million, reflecting ongoing investment in commercialization and R&D.
The company estimates a U.S. prevalence-based market opportunity of $10.5 billion (339,000 patients) for current HFrEF indications, which could rise to $30.5 billion (983,000 patients) if a new pivotal IDE trial in a broader heart failure population is successful. Multiple clinical studies have shown Barostim can improve walking distance, quality of life, functional class, and key biomarkers while maintaining high safety margins.
CVRx, Inc. reported fourth quarter 2025 revenue of $16.0 million, up 4% year over year, with U.S. revenue of $14.9 million and gross margin improving to 86%. The company remained unprofitable, posting a quarterly net loss of $11.9 million, or $0.46 per share.
For full year 2025, revenue reached $56.7 million, a 10% increase, while net loss narrowed to $53.3 million from $60.0 million. CVRx expanded to 252 active implanting centers and 53 U.S. sales territories, and maintained a high 85% gross margin.
The company initiated the large BENEFIT-HF trial, targeting up to 2,500 patients and potential threefold expansion of the Barostim addressable market, with expected net costs of $20–$30 million over five to seven years. CVRx also upsized its Innovatus debt facility to up to $100 million and borrowed an additional $10 million, ending 2025 with $75.7 million in cash and cash equivalents and guiding 2026 revenue to $63.0–$67.0 million.
Johnson & Johnson, together with its subsidiary Johnson & Johnson Innovation – JJDC, Inc., reports beneficial ownership of 4,024,861 shares of CVRx, Inc. common stock, representing 15.4% of the class as of the measurement date. JJDC directly owns the shares, and Johnson & Johnson may be deemed to indirectly own them through its wholly owned subsidiary.
The ownership percentage is calculated against 26,210,109 CVRx common shares outstanding as of October 30, 2025, with the ownership position reported as of December 31, 2025. All voting and dispositive power over these shares is reported as shared rather than sole.
CVRx, Inc. entered into an Open Market Sale Agreement with Jefferies LLC that allows the company to offer and sell shares of its common stock in an at-the-market program. Under this arrangement, CVRx may issue shares with an aggregate offering amount of up to $50.0 million, from time to time, through Jefferies acting as sales agent.
Any sales will be made as at-the-market offerings under an effective Form S-3 shelf registration and related prospectus supplement. Jefferies will receive a commission of up to 3.0% of the gross proceeds from any shares sold, and CVRx will also cover certain related expenses. The company states that it intends to use any net proceeds primarily for working capital and general corporate purposes, and is not obligated to sell any specific amount under the agreement.
CVRx is offering up to $50,000,000 of common stock through an at-the-market program with Jefferies as sales agent. Shares may be sold from time to time on Nasdaq or other markets, with Jefferies earning a commission of up to 3% of the gross proceeds and treated as an underwriter. The company plans to use any net proceeds primarily for working capital and general corporate purposes.
At an illustrative price of $8.45 per share, CVRx assumes selling 5,917,159 shares, which would generate approximately $50.0 million in gross proceeds and increase net tangible book value from $1.68 to $2.87 per share. New investors in that scenario would see immediate dilution of $5.58 per share. As of September 30, 2025, CVRx had 26,193,733 shares outstanding, plus additional options, warrants and plan reserves that could add further dilution if exercised or issued.
CVRx, Inc. amended its term loan agreement on January 9, 2026, increasing total term loan availability by $50 million to up to $100 million, extending interest-only payments to four years from the closing date and pushing final maturity to May 9, 2031. The interest rate is now a floating rate equal to the greater of the prime rate or 6.75%, plus a margin of 2.65%, which falls to 2.00% after two consecutive quarters of positive adjusted EBITDA. The company immediately borrowed an additional $10 million, bringing total term loans outstanding to $60 million, and may draw a further $40 million if future revenue and market capitalization milestones are met.
CVRx expects fourth-quarter 2025 revenue of about $15.9–$16.1 million, up roughly 4–5% from $15.3 million a year earlier, and full-year 2025 revenue of about $56.5–$56.7 million, up 10–11% from $51.3 million in 2024. As of December 31, 2025, it had $75.7 million in cash and cash equivalents, 252 active implanting centers, and 53 U.S. sales territories.
The FDA granted an investigational device exemption for the BENEFIT-HF trial of the Barostim device in an expanded heart failure population. CVRx has applied to CMS for IDE Category B coverage; if approved, it plans to enroll across about 150 centers in the first half of 2026, with enrollment expected to complete within five years and a two-year follow-up. Net trial costs are expected at $20–$30 million, and a successful outcome could expand Barostim’s U.S. addressable market from roughly 339,000 to 983,000 patients, increasing the estimated sales opportunity from $10.5 billion to $30.5 billion.
CVRx, Inc. filed a shelf registration statement on Form S-3 to offer and sell up to $150,000,000 of securities from time to time after effectiveness. The shelf covers common stock, preferred stock, debt securities, stock purchase contracts, warrants, rights, and units, with specific terms to be set in prospectus supplements.
Offerings may be made through underwriters, dealers, agents, or directly, at fixed, market-related, or negotiated prices. Use of proceeds will be described in the applicable supplement. CVRx’s common stock trades on Nasdaq under the symbol CVRX; on November 3, 2025, the last reported sale price was $10.36 per share.
CVRx, Inc. reported third‑quarter results showing steady top‑line growth and improved margins while remaining unprofitable. Revenue for the three months ended September 30, 2025 was $14.7 million, up 10% year over year, driven mainly by U.S. heart failure implants. Gross margin rose to 87% from 83% on higher average selling prices and manufacturing efficiencies.
Operating expenses were $25.0 million, yielding a loss from operations of $12.3 million. Net loss was $12.9 million (basic and diluted net loss per share $0.49). For the nine months, revenue reached $40.6 million (up 13%) with a net loss of $41.4 million.
Cash and cash equivalents were $85.1 million as of September 30, 2025, with $50.0 million of long‑term debt outstanding under the Innovatus loan. The company issued 543,462 shares via its ATM for gross proceeds of $9.5 million during the nine‑month period. CMS finalized the 2026 Medicare Physician Fee Schedule adding Category I CPT codes for Barostim, effective January 1, 2026.